Novel N-4-(5-Amino-7-substituted-triazolotriazinepiperazin-1-yl) Norfloxacin Analogues Exhibit Potent and Selective Anticancer Activity via Topoisomerase Inhibition, Cell-Cycle Arrest, and Apoptosis in A 431 Skin Carcinoma Cells
Pharmaceuticals · 22.04.2026 · 19 (5) · 657
DOI: 10.3390/ph19050657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 22.04.2026. Verfasst von Ahmed M El-Saghier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, Faculty of Science, Sohag University, Sohag 282524, Egypt. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Skin carcinoma is among the most common cancers globally, necessitating the urgent development of innovative chemotherapeutic drugs that exhibit great selectivity and diminished toxicity towards normal cells. This study assessed a series of recently synthesized compounds (4–15) for screening their anticancer efficacy against A 431 human skin carcinoma cells to find effective and selective treatment candidates.
Methods
Compounds were synthesized via a one-pot, three-component reaction. Cytotoxicity was evaluated using the MTT assay, with 5-fluorouracil (5-FU) as the reference standard, which exhibited potent activity against A 431 skin cancer cells. The activity of these drugs against normal BJ cells was evaluated, with mechanistic investigations encompassing topoisomerase I/II enzyme inhibition, cell-cycle analysis, and Annexin V–FITC/PI apoptosis assays.
Results
Most compounds exhibited dose-dependent cytotoxicity, with compound 14 demonstrating the highest potency (IC50 = 76.7 µg/mL), exceeding that of 5-FU (IC50 = 83.7 µg/mL) while preserving selectivity for BJ cells. Compound 14 exhibited moderate inhibition of topoisomerases I and II (IC50 values of 17.5 and 17.3 µM), as confirmed by docking studies. Flow cytometry indicated G0/G1 phase arrest (64.09% vs. 58.18% in control), while apoptosis assays confirmed induction of both early and late apoptosis, accompanied by significant necrosis.
Conclusions
Compound 14 is the most efficacious and selective drug in this series, functioning through topoisomerase inhibition, G0/G1 cell cycle arrest, and apoptosis, thereby representing a strong candidate for subsequent preclinical research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chemistry Department, Faculty of Science, Sohag University, Sohag 282524, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy-Aljmail, Sabratha University, Sabratha 250, Libya.
- Institute for Biological and Chemical Systems, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, New Valley University, New Valley 72511, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, New Valley National University, New Valley 72511, Egypt.
ORCID-Profile: Ahmed M El-Saghier, Amany M Hamed, Stefan Bräse, Hossameldin A Aziz
Zitieren
APA
El-Saghier, A. M., Hamed, A. M., Abosella, L., Bräse, S., & Aziz, H. A. (2026). Novel N-4-(5-Amino-7-substituted-triazolotriazinepiperazin-1-yl) Norfloxacin Analogues Exhibit Potent and Selective Anticancer Activity via Topoisomerase Inhibition, Cell-Cycle Arrest, and Apoptosis in A 431 Skin Carcinoma Cells. Pharmaceuticals, 19(5), 657. https://doi.org/10.3390/ph19050657
Vancouver
El-Saghier AM, Hamed AM, Abosella L, Bräse S, Aziz HA. Novel N-4-(5-Amino-7-substituted-triazolotriazinepiperazin-1-yl) Norfloxacin Analogues Exhibit Potent and Selective Anticancer Activity via Topoisomerase Inhibition, Cell-Cycle Arrest, and Apoptosis in A 431 Skin Carcinoma Cells. Pharmaceuticals. 2026;19(5):657. doi:10.3390/ph19050657
BibTeX
@article{ElSaghier2026,
author = {El-Saghier, Ahmed M and Hamed, Amany M and Abosella, Laila and Bräse, Stefan and Aziz, Hossameldin A},
title = {Novel N-4-(5-Amino-7-substituted-triazolotriazinepiperazin-1-yl) Norfloxacin Analogues Exhibit Potent and Selective Anticancer Activity via Topoisomerase Inhibition, Cell-Cycle Arrest, and Apoptosis in A 431 Skin Carcinoma Cells},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {5},
pages = {657},
doi = {10.3390/ph19050657}
}
EUVIMED